Lozivate Cream contains Clobetasol propionate 0.05% w/w, a potent topical corticosteroid indicated for the treatment of various inflammatory and pruritic dermatoses responsive to corticosteroid therapy. It exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by inhibiting multiple inflammatory cytokines and mediators involved in the pathogenesis of skin disorders. Lozivate Cream is primarily used in conditions such as psoriasis, eczema, lichen planus, and severe dermatitis where rapid symptomatic relief is required. The cream formulation facilitates easy application and absorption, providing effective localized treatment with minimal systemic exposure when used as directed. It is intended for short-term use due to the risk of adverse effects associated with prolonged corticosteroid therapy, including skin atrophy, telangiectasia, and hypothalamic-pituitary-adrenal axis suppression. Patients should apply a thin layer to the affected area once or twice daily, avoiding occlusive dressings unless prescribed. Lozivate Cream is contraindicated in viral, bacterial, or fungal skin infections and should not be used on the face, groin, or axillae without medical supervision. Caution is advised in pediatric and elderly populations. Discontinuation should be gradual to prevent rebound symptoms. Always consult a healthcare professional before initiating therapy with Lozivate Cream.